LGT Capital Partners LTD. Sells 14,327 Shares of IDEXX Laboratories, Inc. $IDXX

LGT Capital Partners LTD. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 105,998 shares of the company’s stock after selling 14,327 shares during the quarter. IDEXX Laboratories comprises approximately 3.6% of LGT Capital Partners LTD.’s portfolio, making the stock its 9th largest holding. LGT Capital Partners LTD. owned about 0.13% of IDEXX Laboratories worth $71,711,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the third quarter valued at $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $29,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares in the last quarter. Wormser Freres Gestion boosted its holdings in shares of IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 47 shares in the last quarter. Finally, WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at about $30,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Piper Sandler lowered their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Citigroup assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Finally, UBS Group lowered their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Stock Down 0.2%

IDXX stock opened at $561.17 on Tuesday. The company has a market cap of $44.27 billion, a P/E ratio of 41.32, a P/E/G ratio of 3.08 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98. The company’s 50-day moving average price is $562.81 and its 200 day moving average price is $631.11. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.